Latest Recruitment News

Third Age Health Services posted a 17.9% revenue increase and 24.7% profit rise for FY26, driven by strategic acquisitions and expansion in aged residential care services.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.

1414 Degrees has initiated the scale-up of its SiNTL silicon anode production, moving beyond lab-scale to manufacturer-relevant volumes. This step unlocks formal third-party evaluations and OEM engagement, with full-stack battery development targeting drones, UAVs, and satellites underway.

The Therapeutic Goods Administration has broadened the range of clinicians eligible to participate in psychedelic-assisted psychotherapy, a move set to speed up recruitment and improve patient access across Emyria’s national Empax network.

Neurizon Therapeutics has boosted the participant count in its HEALEY ALS Platform Trial Regimen I from 160 to 240, capitalising on faster enrolment and philanthropic support to maintain costs and accelerate topline results to early Q3 2027.

Minrex Resources is set to ramp up its flagship Tlamino Gold Project in Serbia with a fully funded 7,000m drilling program aimed at upgrading its resource classification and refreshing project economics in a dramatically improved metals price environment.

Biome Australia has launched a multi-centre clinical trial for its proprietary probiotic BMB18, adding a prestigious Greek university to its research network and commencing recruitment within the expected timeline.

Brightstar Resources has given the green light to its Goldfields Project, commencing construction of a 1.5Mtpa processing plant at Laverton. First gold production is slated for June 2027, backed by full funding and regulatory approvals.

Avecho Biotechnology has wrapped up the treatment phase for its pivotal Phase III insomnia trial involving 244 participants, setting the stage for an interim efficacy analysis expected in late June 2026.

Patrys has appointed CMAX and Alithia Life Sciences to lead its Phase 1A clinical trial operations for RLS-2202, advancing its injectable quetiapine program toward first-in-human testing in Q3 2026, pending ethics approval.

Cleo Diagnostics has laid out a clear U.S. reimbursement pathway for its ovarian cancer test, leveraging an existing CPT code to enable early market entry and data collection ahead of FDA clearance.

Amplia Therapeutics has launched a Phase 2b trial testing a new daily dosing regimen of narmafotinib combined with chemotherapy in advanced pancreatic cancer, aiming to accelerate progress towards a pivotal Phase 3 study.